Algeria Launches New Pharmaceutical Units to Boost Local Drug Production
- Editorial Team
- 7 hours ago
- 1 min read

Algerian Minister of the Pharmaceutical Industry, Wassim Kouidri, announced the creation of new Saidal manufacturing units in Ouled Djellal, Ouargla, and Tamanrasset, as part of a national plan to achieve pharmaceutical sovereignty and ensure medicine availability nationwide.
Speaking during a plenary session of the National People’s Assembly (APN) on Thursday, Minister Wassim Kouidri revealed that public group Saidal will soon establish new pharmaceutical production units in three southern wilayas.
The initiative aims to decentralize production, address regional disparities, and strengthen industrial presence in the south—areas that often face supply challenges. It also supports Algeria’s broader strategy to reduce dependency on imports and enhance national health security.
Kouidri emphasized the government’s collaboration with the Algerian Investment Promotion Agency (AAPI) to attract pharmaceutical investment in inland and newly established wilayas. These regions offer extensive land potential and opportunities for job creation, supporting local economies.
The minister outlined the sector’s roadmap, which prioritizes domestic production of raw materials essential for manufacturing key medicines, including treatments for diabetes, cancer, cardiovascular diseases, and antibiotics. Several strategic projects are already underway and expected to become operational by the end of 2026.
Towards Local Production of Dental Anesthetics
Kouidri also confirmed that four national companies will begin producing dental anesthetic substances locally starting next year. This move is designed to meet growing demand from healthcare professionals and prevent the shortages experienced in recent years.
With new factories, local raw material production, and strategic investments planned through 2026, Algeria is advancing toward a self-sufficient, modern pharmaceutical industry. The objective: ensure consistent access to medicines, lower import costs, and foster balanced economic growth across all regions.